Dimerization-induced allostery in protein kinase regulation

Trends in Biochemical Sciences

Volumn 39, Issue 10, 2014, Pages 475-486

  Lavoie, Hugo ^a   Li, John J ^b,c   Thevakumaran, Neroshan ^b,c   Therrien, Marc ^a,d   Sicheri, Frank ^b,c  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Allosteric regulation; Dimerization; Protein kinases; Pseudokinase

Indexed keywords

B RAF KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GSK 2656157; PARADOX BREAKER 04; PLX 7904; PROTEIN IRE1; PROTEIN KINASE; PROTEIN KINASE R; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAS PROTEIN; RIBONUCLEASE L; UNCLASSIFIED DRUG; 2-5A-DEPENDENT RIBONUCLEASE; EIF2ALPHA KINASE, MOUSE; ERN1 PROTEIN, HUMAN; RIBONUCLEASE;

ALLOSTERISM; ALPHA HELIX; CARCINOGENESIS; CATALYSIS; DIMERIZATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG RESISTANCE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME REGULATION; HUMAN; NONHUMAN; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; CHEMICAL STRUCTURE; GENE EXPRESSION REGULATION; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

ALLOSTERIC REGULATION; ENDORIBONUCLEASES; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RAF KINASES; SIGNAL TRANSDUCTION;

EID: 84922783539     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.08.004     Document Type: Review

References (68)

1. Miele A.E., et al. Hemoglobin allostery: new views on old players. J. Mol. Biol. 2013, 425:1515-1526.
2. Perutz M.F. Stereochemistry of cooperative effects in haemoglobin. Nature 1970, 228:726-739.
3. Changeux J-P. Allostery and the Monod-Wyman-Changeux model after 50 years. Annu. Rev. Biophys. 2012, 41:103-133.
4. Manning G., et al. Evolution of protein kinase signaling from yeast to man. Trends Biochem. Sci. 2002, 27:514-520.
5. Hunter T. Protein kinase classification. Meth. Enzymol. 1991, 200:3-37.
6. Nolen B., et al. Regulation of protein kinases controlling activity through activation segment conformation. Mol. Cell 2004, 15:661-675.
7. Kornev A.P., Taylor S.S. Defining the conserved internal architecture of a protein kinase. Biochim. Biophys. Acta 2010, 1804:440-444.
8. Eyck, Ten L.F., et al. Conserved spatial patterns across the protein kinase family. Biochim. Biophys. Acta 2008, 1784:238-243.
9. De Bondt H.L., et al. Crystal structure of cyclin-dependent kinase 2. Nature 1993, 363:595-602.
10. Jeffrey P.D., et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376:313-320.
11. Endicott J.A., et al. The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 2012, 81:587-613.
12. Sicheri F., et al. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997, 385:602-609.
13. Xu W., et al. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997, 385:595-602.
14. Filippakopoulos P., et al. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 2008, 134:793-803.
15. Yan Q., et al. Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker. Mol. Cell. Biol. 2013, 33:2188-2201.
16. Pellicena P., Kuriyan J. Protein-protein interactions in the allosteric regulation of protein kinases. Curr. Opin. Struct. Biol. 2006, 16:702-709.
17. Endres N.F., et al. Regulation of the catalytic activity of the EGF receptor. Curr. Opin. Struct. Biol. 2011, 21:777-784.
18. Jura N., et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol. Cell 2011, 42:9-22.
19. Udell C.M., et al. Mechanistic principles of RAF kinase signaling. Cell. Mol. Life Sci. 2010, 68:553-565.
20. Baljuls A., et al. It takes two to tango - signalling by dimeric Raf kinases. Mol. Biosyst. 2013, 9:551-558.
21. Forbes S.A., et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011, 39:D945-D950.
22. Roskoski R. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 2012, 10.1016/j.phrs.2012.04.005.
23. Sundaram M., Han M. The C. elegans ksr-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell 1995, 83:889-901.
24. Douziech M., et al. A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila. Genes Dev. 2006, 20:807-819.
25. Rajakulendran T., et al. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461:542-545.
26. Cheng S., Niv M.Y. Molecular dynamics simulations and elastic network analysis of protein kinase B (Akt/PKB) inactivation. J. Chem. Inf. Model. 2010, 50:1602-1610.
27. Brennan D.F., et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 2011, 472:366-369.
28. Zeqiraj E., van Aalten D.M.F. Pseudokinases-remnants of evolution or key allosteric regulators?. Curr. Opin. Struct. Biol. 2010, 20:772-781.
29. Lavoie H., et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat. Chem. Biol. 2013, 9:428-436.
30. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
31. Huang H., et al. Dimeric structure of pseudokinase RNase L bound to 2-5A reveals a basis for interferon-induced antiviral activity. Mol. Cell 2014, 53:221-234.
32. Han Y., et al. Structure of human RNase L reveals the basis for regulated RNA decay in the IFN response. Science 2014, 343:1244-1248.
33. Mineo C., et al. Physical association with ras enhances activation of membrane-bound raf (RafCAAX). J. Biol. Chem. 1997, 272:10345-10348.
34. Chong H., Guan K-L. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J. Biol. Chem. 2003, 278:36269-36276.
35. Tran N.H., et al. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J. Biol. Chem. 2005, 280:16244-16253.
36. Plowman S.J., et al. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:15500-15505.
37. Dementiev A. K-Ras4B lipoprotein synthesis: biochemical characterization, functional properties, and dimer formation. Protein Expr. Purif. 2012, 10.1016/j.pep.2012.04.021.
38. Güldenhaupt J., et al. N-Ras forms dimers at POPC membranes. Biophys. J. 2012, 103:1585-1593.
39. Lin W-C., et al. H-Ras forms dimers on membrane surfaces via a protein-protein interface. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:2996-3001.
40. Baska F., et al. Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors. Curr. Med. Chem. 2014, 21:1938-1955.
41. Hatzivassiliou G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
42. Poulikakos P.I., et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
43. Gibney G.T., et al. Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma. Nat. Rev. Clin. Oncol. 2013, 10:390-399.
44. Holderfield M., et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat. Rev. Cancer 2014, 14:455-467.
45. Macdonald-Obermann J.L., et al. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. J. Biol. Chem. 2013, 288:30773-30784.
46. Freeman A.K., et al. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 2013, 49:751-758.
47. Le K., et al. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 2013, 26:509-517.
48. Wek R.C., et al. Coping with stress: eIF2 kinases and translational control. Biochem. Soc. Trans. 2006, 34:7-11.
49. Dey M., et al. Conserved intermolecular salt bridge required for activation of protein kinases PKR, GCN2, and PERK. J. Biol. Chem. 2007, 282:6653-6660.
50. Dever T.E. Gene-specific regulation by general translation factors. Cell 2002, 108:545-556.
51. Ung T.L., et al. Heterologous dimerization domains functionally substitute for the double-stranded RNA binding domains of the kinase PKR. EMBO J. 2001, 20:3728-3737.
52. Dar A.C., et al. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005, 122:887-900.
53. Dey M., et al. Mechanistic link between PKR dimerization, autophosphorylation, and eIF2alpha substrate recognition. Cell 2005, 122:901-913.
54. Cui W., et al. The structure of the PERK kinase domain suggests the mechanism for its activation. Acta Crystallogr. D: Biol. Crystallogr. 2011, 67:423-428.
55. Ortiz-Lombardía M., et al. Crystal structure of the catalytic domain of the PknB serine/threonine kinase from Mycobacterium tuberculosis. J. Biol. Chem. 2003, 278:13094-13100.
56. Greenstein A.E., et al. Allosteric activation by dimerization of the PknD receptor Ser/Thr protein kinase from Mycobacterium tuberculosis. J. Biol. Chem. 2007, 282:11427-11435.
57. Lee K.P.K., et al. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell 2008, 132:89-100.
58. Korennykh A.V., et al. The unfolded protein response signals through high-order assembly of Ire1. Nature 2009, 457:687-693.
59. Padyana A.K., et al. Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J. Biol. Chem. 2005, 280:29289-29299.
60. Lageix S., et al. Enhanced interaction between pseudokinase and kinase domains in Gcn2 stimulates eIF2α phosphorylation in starved cells. PLoS Genet. 2014, 10:e1004326.
61. Wiseman R.L., et al. SnapShot: the unfolded protein response. Cell 2010, 140:590-590.e2.
62. Chakrabarti A., et al. New insights into the role of RNase L in innate immunity. J. Interferon Cytokine Res. 2011, 31:49-57.
63. Barthe P., et al. The structure of PknB extracellular PASTA domain from Mycobacterium tuberculosis suggests a ligand-dependent kinase activation. Structure 2010, 18:606-615.
64. Ma T., et al. Suppression of eIF2α kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat. Neurosci. 2013, 16:1299-1305.
65. Nakamura T., et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010, 140:338-348.
66. Atkins C., et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013, 73:1993-2002.
67. Brooks A.J., et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 2014, 344:1249783.
68. Koppikar P., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.